PGXL to utilize AutoGenomics' automated INFINITI analyzer for personalized medicine applications

PGXL Labs, an internationally recognized pioneer in personalized medicine testing, announced today that it has established a collaborative partnership with AutoGenomics, Inc. wherein they will utilize the automated INFINITI^® analyzer for several different personalized medicine applications.

“The versatility of our BioFilmChip Microarray technology allows us to rapidly develop new test applications to meet the evolving needs in companion diagnostic testing and enable PGXL Labs to expand the array of personalized medicine tests.”

"The automation provided by the AutoGenomics' INFINITI® Analyzer will enhance workflow in our laboratories," said Mark Linder, Executive Vice-President of Operations and Co-Founder of PGXL Laboratories. He further stated that "with their comprehensive menu of molecular applications in the pharmacogenetics arena, we have found AutoGenomics to be a very suitable partner in meeting our emerging testing needs."

"We are excited to partner with PGXL Labs who have pioneered in bringing the benefits of pharmacogenetics testing to patients across the country," said Ramanath Vairavan, Senior Vice President of AutoGenomics. "The versatility of our BioFilmChip Microarray technology allows us to rapidly develop new test applications to meet the evolving needs in companion diagnostic testing and enable PGXL Labs to expand the array of personalized medicine tests."

PGXL plans to utilize the INFINITI^® Warfarin Assay and the CYP450 2C19 assay, both of which have been cleared by the FDA. In addition, they will plan to use the INFINITI^® KRAS-BRAF test.